See also this year's filing and all EDGAR filings for this company.
PDF Report 0001582313_2023_Xenon_Pharmaceuticals_Inc.pdf
Logs
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss 2': 2, '100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss': 15}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001582313, Xenon Pharmaceuticals Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 600,298,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 6,500,000 |
| 3 | remainder_Assets | 147,348,000 |
| 4 | LiabilitiesCurrent | 22,702,000 |
| 5 | LiabilitiesNoncurrent | 9,947,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 32,810,000 |
| 9 | ResearchAndDevelopmentExpense | 105,767,000 |
| 10 | remainder_Expenses | 118,000 |
| 11 | remainder_Revenues | 9,434,000 |
| 12 | remainder_NetIncome | 3,888,000 |
| 13 | remainder_ComprehensiveNetIncome | -2,010,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 754,146,000 |
| 1 | Liabilities | 32,649,000 |
| 2 | Expenses | 138,695,000 |
| 3 | Revenues | 9,434,000 |
| 4 | StockholdersEquity | 721,497,000 |
| 5 | NetIncome | -125,373,000 |
| 6 | ComprehensiveNetIncome | -126,378,000 |
| 7 | BaseVar | 470,411,000 |
| 8 | EconomicCapitalRatio | 2.83 |
Edgar->Model Mapping
Feature Distribution
Change over Time
